Drug Discovery

Can Engineered Bacteria Lead the Future of Cancer Treatment?
Research & Development Can Engineered Bacteria Lead the Future of Cancer Treatment?

The relentless pursuit of highly effective oncological interventions has historically been hampered by the inability of traditional pharmaceutical agents to distinguish accurately between malignant cells and healthy physiological structures. While chemotherapy and systemic radiation have saved

How Does Ezrin’s Dual Role Drive Bone Cancer Spread?
Research & Development How Does Ezrin’s Dual Role Drive Bone Cancer Spread?

The silent progression of osteosarcoma remains one of the most daunting challenges in modern pediatric oncology, often remaining undetected until the malignancy has already begun its journey to distant organs. While medical science has mastered the art of treating localized bone tumors through a

Is TBC1D9B the Master Switch for Cellular Metabolism?
Research & Development Is TBC1D9B the Master Switch for Cellular Metabolism?

The human cell operates as a high-speed logistics hub where the physical location of cargo determines the fate of the entire biological operation. For decades, biology textbooks have described lysosomes as simple waste disposal units—tiny acidic balloons drifting through the cytoplasm to dissolve

Metabolic Enzyme PFK Found to Drive Cell Division via RNA
Research & Development Metabolic Enzyme PFK Found to Drive Cell Division via RNA

The boundaries between how a cell generates energy and how it decides to multiply have long been viewed as separate chapters in the book of biology, yet recent evidence suggests these processes are inextricably linked by a single, versatile protein. For over seventy years, scientists categorized

Pfizer’s Next-Gen Cancer Drug Cuts Progression Risk by 40%
Research & Development Pfizer’s Next-Gen Cancer Drug Cuts Progression Risk by 40%

The current oncology landscape is defined by an urgent need for therapies that can bypass resistance mechanisms in advanced breast cancer while maintaining patient quality of life. Pfizer’s latest clinical data for atirmociclib suggests a significant advancement in achieving this balance through a

Why Did Bicycle Therapeutics Halt Its Bladder Cancer Drug?
Research & Development Why Did Bicycle Therapeutics Halt Its Bladder Cancer Drug?

The high-stakes landscape of biotechnology often demands that even the most innovative firms execute sudden, clinical-grade course corrections to ensure their long-term survival. Bicycle Therapeutics recently demonstrated this reality by announcing a drastic shift in its corporate strategy, which

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later